

MINUTES OF FINANCIAL EVALUATION COMMITTEE MEETING FOR TENDER NO.- BMSIC/DRUGS/24-12/RE-TENDER (RE-TENDER FOR RATE CONTRACT AND SUPPLY OF QUADRIVALENT HUMAN PAPILLOMA VIRUS (SEROTYPES 6, 11, 16 & 18) VACCINE (RECOMBINANT) (QHPV) FOR DIFFERENT HEALTHCARE FACILITIES OF STATE OF BIHAR).

Date: 16th December 2024

Venue: BMSICL Conference Hall.

The **Financial Evaluation Committee Meeting for Tender No. BMSIC/DRUGS/24-12/RE-TENDER** was held on **16th December 2024** under the Chairmanship of **Managing Director, BMSICL**. The other committee members present in the meeting were:

1. Dr. Manoj Kumar Choudhary, Director in Chief, Health Department, GoB.
2. Smt. Kumari Seema, CGM (Supply Chain), BMSICL.
3. Sh. Harendra Ram, GM (Procurement), BMSICL.
4. Sh. Rajesh Kumar, Administrative Officer-cum-I/C Procurement, SHSB.
5. Sh. Shrawan Kumar, Internal Financial Advisor (IFA), of Health Department, GoB.
6. Dr. Vidyapati Choudhary, Principal PMCH, Patna.
7. Sh. Ramendra Kumar, GM (Finance), BMSICL.

2. The Details of the invited tender are as follows:

1. Tender Reference No. BMSIC/DRUGS/24-12/RE-TENDER.
2. Tender floated date- 26/11/2024.
3. Last date of submission of online bids- 11/12/2024.

3. The Tender has been floated on e-proc2 Portal for the Drug Quadrivalent Human Papilloma Virus (Serotypes 6, 11, 16 & 18) Vaccine (Recombinant) (qHPV) (0.5 ml - 1 dose) Injection.

4. Total two (02) bidders were found to have successfully submitted their bids on the e-proc2 online system. The submission status of original hard copy of Earnest Money Deposit (EMD), till the stipulated time was found as following: -

S.N.	Name of the Firm	Online submission status of bids on E-Proc2	Requisite Amount of EMD receipt Status	Remarks
1	M/s MSD Pharmaceuticals Private Limited	Ok	Received	Ok
2	M/s Serum Institute of India Private Limited	Ok	Received	Ok

5. The item wise bid received status was as follows:

S.N.	Name of the Drug	Participating Firms	No. of Bids
1	Quadrivalent Human Papilloma Virus (Serotypes 6, 11, 16 & 18) Vaccine (Recombinant) (qHPV)	M/s MSD Pharmaceuticals Private Limited	2
		M/s Serum Institute Of India Private Limited	

6. It was therefore unanimously decided by TEC to recommend for evaluating the both received bids.

7. After evaluating the bids and close examination of the documents submitted by the firms, the Drug wise technical evaluation findings for each firm were recorded by TEC its meeting dated 13.12.2024 with the help of Drugs Inspectors deputed at BMSICL as follows:

S.N.	Name of the Drug	Participating firms	Technical Qualification Status (Qualified/ Disqualified)	Remarks
1	Quadrivalent Human Papilloma Virus (Serotypes 6, 11, 16 & 18) Vaccine (Recombinant) (qHPV)	M/s MSD Pharmaceuticals Private Limited	Qualified	Ok
		M/s Serum Institute of India Private Limited	Qualified	Ok

8. According to the comparative chart above, a total of two (02) bidders namely, M/s MSD Pharmaceuticals Private Limited & M/s Serum Institute Of India Private Limited were found technically qualified.

9. It was therefore unanimously decided by TEC in its meeting dated 13.12.2024 to recommend for opening of the financial bids of the technically qualified bidders on e-proc2 portal.

10. Accordingly, the financial bids of technically qualified bidders were opened today on e-proc2 portal, in which the following result has been observed: -

S. N.	Name of the Drug	Participating firms	Quoted Rate (Rs.) for Each Unit (Excluding GST)	Quoted Rate (Rs.) for Each Unit (Including GST@5%)	Bid Ranking
1	Quadrivalent Human Papilloma Virus (Serotypes 6, 11, 16 & 18) Vaccine (Recombinant) (qHPV)	M/s Serum Institute of India Private Limited	866.67	910	L1
		M/s MSD Pharmaceuticals Private Limited	1495	1569.75	L2

11. As per the comparative chart, the L1 rate is Rs. **910/- (Including GST @ 5%)** per Vial for the product Quadrivalent Human Papilloma Virus (Serotypes 6, 11, 16 & 18) Vaccine (Recombinant) (qHPV) quoted by the firm M/s Serum Institute of India Private Limited. It was unanimously decided by Financial Evaluation Committee to ask the L1 bidder for justify their quoted price for the above said product.

12. The meeting thus concluded with a vote of thanks.

Sd/-
(Ramendra Kumar)
GM (Finance), BMSICL, Patna.

Sd/-
(Dr. Vidyapati Choudhary)
Principal PMCH, Patna.

Sd/-
(Shrawan Kumar)
Internal Financial Advisor, Health Dept., Govt. of Bihar.

Sd/-
(Rajesh Kumar)
Administrative Officer-cum-I/C Procurement, SHSB.

Sd/-
(Harendra Ram)
GM (Procurement), BMSICL, Patna.

Sd/-
(Kumari Seema)
CGM (Supply Chain), BMSICL, Patna.

Sd/-
(Dr. Manoj Kumar Choudhary)
Director in Chief, Health Dept., Govt. of Bihar.

Sd/-
(Dharmendra Kumar)
Managing Director, BMSICL.